平均风险女性的乳腺癌筛查:迈向个体化筛查
本文综述了平均风险女性乳腺癌筛查的争议与最新进展,指出美国内科医师学会新指南与美国预防服务工作组及欧洲指南推荐相似,但与其他美国专科学会不同,差异源于组织价值观、评价指标及医疗体系结构。多数专科学会认为应在40岁起提供乳腺X线筛查,并通过共享决策讨论获益与风险以实现个体化筛查。
要点
- 多数专科学会认为医生应在40岁起为平均风险女性提供乳腺X线筛查。
- 筛查应通过共享决策讨论获益与潜在风险,以实现个体化筛查策略。
- 假阳性率和惰性癌过度诊断被视为乳腺X线筛查最重要的潜在伤害,但实际后果证据有限。
核心结论
- 筛查目标是诊断无症状早期病变以提高疗效,但最佳筛查频率、开始和结束年龄仍存争议。
- 美国内科医师学会新指南与美国预防服务工作组及欧洲指南推荐相似,但与其他美国专科学会不同。
- 指南差异反映组织价值观、评价筛查结果的指标及医疗体系(个体化或国家组织)的不同。
研究设计与样本
- 本文为综述,无新试验,汇总了随机对照试验的随访信息及美国内科医师学会新指南等文献。
诊断标准与关键数值
- 多数专科学会认为应在40岁起为平均风险女性提供乳腺X线筛查,并通过共享决策讨论获益与潜在风险。
临床应用与阅片要点
- 作者认为医生应在40岁起为平均风险女性提供乳腺X线筛查,并讨论其获益与潜在风险,通过共享决策实现个体化筛查策略。
局限性
- 原文指出假阳性率和过度诊断的实际后果证据有限。
- 原文指出筛查最佳频率、开始和结束年龄仍存争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Breast cancer screening is widely recognized for reducing breast cancer mortality. The objective in screening is to diagnose asymptomatic early stage disease, thereby improving treatment efficacy. Screening recommendations have been widely debated over the past years and controversies remain regarding the optimal screening frequency, age to start screening, and age to end screening. While there are no new trials, follow-up information of randomized controlled trials has become available. The American College of Physicians recently issued a new guidance statement on screening for breast cancer in average-risk women, with similar recommendations to the U.S. Preventive Services Task Force and to European guidelines. However, these guidelines differ from those ofother American specialty societies. The variations reflect differences in the organizations' values, the metrics used to evaluate screening results, and the differences in healthcare organization (individualized or state-organized healthcare). False-positive rates and overdiagnosis of biologically insignificant cancer are perceived as the most important potential harms associated with mammographic screening; however, there is limited evidence on their actual consequences. Most specialty societies agree that physicians should offer mammographic screening at age 40 years for average-risk women and discuss its benefits and potential harms to achieve a personalized screening strategy through a shared decision-making process.
引用
- Bitencourt AG, Rossi Saccarelli C, Kuhl C, et al. Breast cancer screening in average-risk women: towards personalized screening. Br J Radiol. 2019. PMID: 31538501. doi:10.1259/bjr.20190660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。